

A Single Cell Network Profiling (SCNP) view of the immune system

Alessandra Cesano MD, PhD

Nodality Inc.



SOCIETY FOR IMMUNOTHERAPY OF CANCER

October 24-28, 2012 • North Bethesda, MD

WORKSHOP • PRIMER • ANNUAL MEETING



Disclosure Information

The following relationships exist related to this presentation:

Alessandra Cesano

Nodality Inc.: Salary, Shares, Full time Employee

Presentation Map

- Single Cell Network Profiling (SCNP) technology:
 - Principles
 - Industrialization
- Application to immune system profiling



SOCIETY FOR IMMUNOTHERAPY OF CANCER

October 24-28, 2012 • North Bethesda, MD

WORKSHOP • PRIMER • ANNUAL MEETING



Presentation Map

- Single Cell Network Profiling (SCNP) technology:
 - Principles
 - Industrialization
- Application to immune system profiling



SOCIETY FOR IMMUNOTHERAPY OF CANCER



October 24-28, 2012 • North Bethesda, MD

WORKSHOP • PRIMER • ANNUAL MEETING




SCNP foundation technology

- Proprietary phosphoflow signaling technology developed in Dr. Garry Nolan's lab at Stanford University





Functional Pathway Analysis: Closer To Relevant Biology

Increasing insight into relevant biology & drug efficacy:




Key Steps In The SCNP Assay



Correlate Pathway Biology to Efficacy & Outcomes

Node: A signaling readout being measured under **modulation** in a cell to determine its contribution to pathway activity
Node = (Modulator) → (Signaling Readout)

SCNP: Unique Combination of Functional & Customizable Characteristics in One Assay



Presentation Map

- Single Cell Network Profiling (SCNP) technology:
 - Principles
 - Industrialization
- Application to immune system profiling




SOCIETY FOR IMMUNOTHERAPY OF CANCER

October 24-28, 2012 • North Bethesda, MD


WORKSHOP • PRIMER • ANNUAL MEETING



A Complex Assay With Many Components & Dimensions To Track




SCNP assay “industrialization” for application to Clinical Medicine and Drug Development



Industrialization of SCNP assay has been achieved through development of several controls, processes, and infrastructure:


1. Standardization of lab processes and instruments
2. Reagent manufacture and/or qualification
3. Study workflows
4. Built ad hoc informatics infrastructure
5. Pre-analytic sample quality and source tissue specifications
6. Repeatability and reproducibility
7. Flexible for pathway discovery & optimization of molecular/companion diagnostic constituents
8. Rigorously designed to meet CLIA & FDA requirements

Evaluation Of Sample Quality: Defining “Healthy Cells”



- Samples are tested for quality and alignment with predefined, disease-specific cutoffs
 - Cell health is defined as the fraction of cells in a given well that are not undergoing apoptosis as defined by amine aqua stain and cPARP levels


- ▶ Healthy cell % cutoffs are established for each disease/cell subtypes



- Sample evalability criteria are used to exclude these samples from further analysis


Robust Repeatability & Reproducibility Of SCNP Assay Following Sample Cryopreservation

Paired Fresh vs cryopreserved PBMC and BMMC samples from AML patients



- SCNP data is highly concordant between fresh and cryopreserved samples
- 15 of the 19 nodes showed $R > 0.80$ for both tissue types

High-Throughput, High-Content Assays With Many Internal Relationships



Typical Plate Layout

	1	2	3	4	5	6	7	8	9	10	11	12
Cell Line Controls	Autofluorescence	Unmod control cocktail 1	NODE 1	NODE 2	Unmod control cocktail 2	NODE 3	NODE 4	Unmod control cocktail 3	NODE 5	Unmod control cocktail 4	NODE 6	RAINBOW BEADS
Donor 1												
Donor 2												
Donor 3												
Donor 4												
Donor 5												
Donor 6												
Donor 7												

*Multiparametric analysis expands array of node options beyond the number of available fluorophores
Flexible format for different needs, such as IC₅₀s and kinetic studies*

Example of Experimental Data Collected and Analyzed

92 Patient samples

140 plates processed

>8,000 wells of data collected on two flow cytometers


All FCS Files QC'ed

All FCS Files Gated manually

189 Metrics Calculated per sample per tissue type

Database Locked Prior to Unblinding Clinical Data


Reagents, Plate layouts and Controls are finalized in the experimental design phase



- 1. Reagents
 - Antibody cocktails
 - Modulators
- 2. Plate design
- 3. Assay controls

- ▶ Most studies use GMP reagents
 - Internal reagent qualification following standard SOP
 - Longitudinal reproducibility of the data
 - Reagent stability program
- ▶ Antibodies are often combined into cocktails and qualified
 - Biologically meaningful combinations (e.g. same pathway)
 - What data is needed at a single cell level vs. at an aggregate level
 - Are the kinetics the same for all components of the cocktail
 - Fluorophore combinations
 - Gating markers

Internal software used to layout plates at user's desk: Maximize cytometer usage and minimize errors



- ▶ Pull down all key components from pre-defined inventory item
 - No manual typing
- ▶ Templating and rapid cloning
- ▶ Export all meta-data to layout files
 - Antibodies, modulators, samples
 - Cytometer settings
 - Detector voltages and compensation

Assay and Instrument controls on every plate

1. Reagents
2. Plate design
3. Assay controls


	1	2	3	4	5	6	7	8	9	10	11	12
Cell Line Controls	Autofluorescence	Unmod control cocktail 1	NODE 1	NODE 2	Unmod control cocktail 2	NODE 3	NODE 4	Unmod control cocktail 3	NODE 5	Unmod control cocktail 4	NODE 6	RAINBOW BEADS
Donor 1												
Donor 2												
Donor 3												
Donor 4												
Donor 5												
Donor 6												
Donor 7												

- ▶ Cell line controls undergo all steps of the SCNP process
 - Thawing
 - Modulation
 - Staining
 - Acquisition
- ▶ Typically used as positive controls

- ▶ Daily QC of instrument
- ▶ Rainbow beads are used as instrument controls and to calibrate the raw intensity value






$ERF = a + b^*MFI$

Linear calibration
derived for each
plate and color




Functional Signaling Requires Appropriate Metrics That Are Different From Those Used To Quantify Surface/Static Markers

- Calibrated instruments, standardized reagents, rigorous data tracking allow for robust biological interpretations
- Specific biological interpretations require different functional readouts




SCNP Data Has Various Characteristics at Various Levels of Detail




Analysis and visualization of SCNP data typically involves comparing data from one part of the characteristics space with another at an appropriate level of detail

SCNP Platform Is Supported By A Robust Informatics Infrastructure

Front end user application with a rich User Interface (UI)





Back end Toolkit for flexibility with custom works flow and data analytics



- Flexible, instrument agnostic experimental design tool
- Exploit rich UI framework in .NET
- Integration with sharepoint and report generation

- SCNP specific data management
- Data analytics on clinical studies
- Use Python as a glue
 - Numerics, R, plotting, office tools
- FCS file, WinList and FlowJo file parsing

SCNP Assay Results Are Reproducible Longitudinally



Results incorporate variance due to instruments, assays, reagents, operators, laboratory sites, sample storage

Presentation Map

- Single Cell Network Profiling (SCNP) technology:
 - Principles
 - Industrialization
- Application to immune system profiling



SOCIETY FOR IMMUNOTHERAPY OF CANCER

October 24-28, 2012 • North Bethesda, MD


WORKSHOP • PRIMER • ANNUAL MEETING



SCNP-based Tools Developed To date to Monitor Immune Signaling Biology - Repertoire Is Constantly Expanding

- Examination of healthy and disease-associated signaling
 - Healthy immune landscaping studies in various demographic groups
 - Rheumatoid arthritis and systemic lupus erythematosus longitudinal studies
 - Cancer Immunotherapy

CURRENTLY ESTABLISHED NODES AND PHENOTYPIC MARKERS



Healthy Immune Landscape Network Map: Establishing Baseline Signaling For Disease/Therapeutic Characterization



THE JOURNAL OF
IMMUNOLOGY

This information is current as
of January 17, 2012

Single-Cell Network Profiling of Peripheral Blood Mononuclear Cells from Healthy Donors Reveals Age- and Race-Associated Differences in Immune Signaling Pathway Activation

Diane M. Longo, Brent Louie, Santosh Putta, Erik Evensen,
Jason Ptacek, James Cordeiro, Ena Wang, Zoltan Pos,
Rachael E. Hawtin, Francesco M. Marincola and Alessandra
Cesano

J Immunol; Prepublished online 13 January 2012;

Longo et al. *Journal of Translational Medicine* 2012, **10**:113
<http://www.translational-medicine.com/content/10/1/113>



JOURNAL OF
TRANSLATIONAL MEDICINE


RESEARCH

Open Access


Racial differences in B cell receptor signaling pathway activation

Diane M Longo^{1*}, Brent Louie¹, Kavita Mathi², Zoltan Pos³, Ena Wang⁴, Rachael E Hawtin¹,
Francesco M Marincola⁴ and Alessandra Cesano¹


Experimental Design For Healthy Immune Landscape Study



Multiple Cell Subsets Are Simultaneously Examined In The Same Sample




Cellular Subsets Reveal Signaling Responses Not Seen In The Entire Cell Population





Most responses would not be detected in the total cell population

Cell Subtype-Specific Signaling Dynamics For Multiple Signaling Nodes Across 60 Healthy Donors

- Identified range of signaling in individual cell subsets
 - Differential magnitude and range of signaling is identifiable for each cell subset
 - Signaling ranges within cell subsets are relatively tight in healthy donors
 - Basis for identification of aberrant signaling




Signaling Correlations Across All Examined Nodes In different cell subsets can be studied



Signaling Correlations Between All Examined Nodes Within Multiple Immune Cell Subsets: An Immune System Signaling Network Map




Master Donor Set Subdivided Into Training & Test Sets




	Master	Training	Test
Number of Donors	60	30	30
Mean Age	48.9	47.9	49.8
Gender	12 Female 48 Male	5 Female 25 Male	7 Female 23 Male
Race	25 African American 34 European American 1 Hispanic	10 African American 19 European American 1 Hispanic	15 African American 15 European American 0 Hispanic

Age-Associated Immune-Signaling Responses Identified In Immune Cell Subsets

A




B




- A) IFN α →pStat5 | CD45RA+ cytotoxic T cells
- B) IL27→pStat5 | CD45RA+ cytotoxic T cells
- C) IL4→pStat6 | CD45RA+ cytotoxic T cells
- D) IL2→pStat5 | CD45RA+ helper T cells


Race-Associated Immune-Signaling Responses Identified



B $\alpha\text{-IgD/LPS} \rightarrow \text{pAkt}$ | B cells



C $\alpha\text{-IgD/LPS} \rightarrow \text{pS6}$ | B cells



Summary Of Healthy Immune Landscaping

- SCNP allows for a systems biology view of signaling of immune system in healthy and disease conditions and under therapeutic pressure (immunomonitoring)
- SCNP Immune system “Landscaping” is being applied to:
 - Define the healthy parameters around key signaling nodes in specific immune cell subsets that are re-routed in autoimmune diseases or cancer (i.e. disease profiling)
 - Define the impact of therapeutics on immune signaling networks (e.g. in cancer immunotherapy and autoimmune disease drugs) – **See Poster N. 92 Titled: *CTLA-4 defines distinct T cell signaling populations in healthy donors and metastatic melanoma patients.*** Presenter: Drew Hotson
 - Create the basis for patient stratification tools and PD assays

Team NODALITY

